CH415587A - Process for the preparation of N-alkyl-substituted 3-methoxy-4-carbamidomethoxyphenylacetic acid alkyl and alkenyl esters - Google Patents

Process for the preparation of N-alkyl-substituted 3-methoxy-4-carbamidomethoxyphenylacetic acid alkyl and alkenyl esters

Info

Publication number
CH415587A
CH415587A CH319466A CH319466A CH415587A CH 415587 A CH415587 A CH 415587A CH 319466 A CH319466 A CH 319466A CH 319466 A CH319466 A CH 319466A CH 415587 A CH415587 A CH 415587A
Authority
CH
Switzerland
Prior art keywords
alkyl
methoxy
substituted
carbamidomethoxyphenylacetic
preparation
Prior art date
Application number
CH319466A
Other languages
German (de)
Inventor
Rudolf Dr Hiltmann
Hartmund Dr Wollweber
Friedrich Dr Hoffmeister
Wirth Wolfgang Dr Prof
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of CH415587A publication Critical patent/CH415587A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182Radicals derived from carboxylic acids
    • C07D295/185Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof

Description

  

  



   Verfahren zur Herstellung von N-alkylsubstituierten   3-Methoxy-4-car. bamidomethoxyphenylessigsäurealkyl-und-alkenylestern   
Es wurde gefunden, dass N-alkylierte 3-Methoxy4-carbamidomethoxyphenylessigsäurealkyl-und-alkenylester intravenös anwendbare, überraschend kurz wirkende Narkotika darstellen, die sich gegenüber den für diesen Zweck bisher ausschliesslich verwandten   Barbitursäurederivaten    im Tierversuch durch einen sehr schnellen Wirkungsabfall und durch das Fehlen des sogenannten ¸overhang¯ auszeichnen.



   Erfindungsgemäss werden diese Verbindungen dadurch hergestellt, dass man entsprechende N-alkylsubstituierte 3-Methoxy-4-carbamidomethoxyphenylessigsäuren mit gesättigten oder ungesättigten aliphatischen Alkoholen verestert oder niedere N-alkylsub  stituierte    3-Methoxy-4-carbamidomethoxyphenylessigsäurealkylester, wie z. B. den Methylester, durch Umestern mit höheren Alkoholen in die entsprechenden höheren Ester überführt.



   Der nach dem erfindungsgemässen Verfahren erhältliche   3-Methoxy-4-N,      N-diäthylcarbamidometh      oxyphenylessigsäure-n-propylester    wurde mit dem   be-    kannten   5-Methyl-5-cyclohexenyl-N-methyl-barbitur-    sauren Natrium verglichen. Dabei ergaben sich beim Hund bei intravenöser Anwendung folgende Resultate :
Verfahrens-Vergleichs produkt produkt a) Dosis 40   mg/kg    40   mg/kg       : g    b)   NarkoseGtadium 8    VI VI c) gesamt-Narkosezeit 17 Min. 166 Min.

      d)    Narkosezeit von
VI-IV in %   der Ge-    samt-Narkosezeit * 47% 17%
Beim Kaninchen liegen gleichsinnige Ergebnisse
Es zeigte sich demnach, dass bei gleicher Dosierung das nach dem erfindungsgemässen Verfahren   gewonnene Produkt dieselbe Narkosetiefe zu    erreichen erlaubt wie das   Vergleichsprodukt,    jedoch bei ganz wesentlich kürzerer   Gesamt-Narkosedauer.   



  (Hierbei wird unter Gesamt-Narkosedauer die Zeit vom Eintritt der Narkose bis zum Verschwinden jeglicher   narkotischer    Symptome verstanden, also bis zu dem Zeitpunkt, zu dem das Tier sich wieder   volSkommen    normal verhält. Auf den Menschen übertragen, gibt dieser Zeitpunkt einen Anhalt für die     Strassenfähigkeit      des narkotisierten Individuums).



   Demzufolge führt das erfindungsgemäss   erhält-    liche Produkt zu einer ganz wesentlich rascheren   Strassenfähigkeit    als das   Vergleichsprodukt,    ein   Vor-    teil, der sich besonders in der kleinen Chirurgie, bei der nur sehr kurze Narkosezeiten erforderlich sind, von ausschlaggebender Bedeutung ist. Abgesehen von dem Vergleichsprodukt sind auch bei den übrigen eingeführten, intravenös anzuwendenden Narkotika solche kurzen   Narkosezeiten-bei    Erreichung des voNen   Toleranzstadiums-nicht    bekannt geworden.



   Beispiel 1
50 g des    3-Methoxy-4-N, N-diäthylcarbamidomethoxy-    phenylessigsäuremethylesters werden in 300 ml n-Propanol gelöst und nach Zugabe von 0, 1 g Natrium-n-propylat an einer wirk  * Narkose-Stadium VI entspricht nach Magnus-Girndt tiefer Narkose mit völliger Reflexlosigkeit ; Narkose-Stadium IV entspricht Seitenlage bei erhaltenem Corneal-und Kneif
Reflex. Die Zeit von Narkose-Stadium VI bis IV ist etwa ein Massstab für die für operative Eingriffe zur Verfügung stehende Zeitspanne. samen Kolonne so lange erhitzt, bis kein Methanol mehr übergeht. Nach   Verjagen    des überschüssigen Propylalkohols destilliert man im Vakuum und erhält 46 g des   
3-Methoxy-4-N, N-diäthylcarbamido- methoxyphenylessigsäure-n-propylesters    von Kp. 0,7 210-212¯.



   Beispiel 2
20 g   3-Methoxy-4-N, N-carbamidomethoxy-    phenylessigsäure   (Schmp.      119-120 ),    die aus dem Methylester durch Verseifung mit Alkali   erhaltlich    ist, wird mit 200 ml 3 % Chlorwasserstoff enthalitendem m-Propylalkohol 8 Stunden am Rückflusskühler erhitzt. Nach   Verjagen      des Lösungsmittels Tiimmt man    in Benzol auf, wäscht mit Natriurncarbonafl¯sung und Wasser und trocknet mit Natriumsulfat. Nach Verjagen des Benzols de  stilliert    man den Rückstand im Vakuum und erhält 19, 8 g
3-Methoxy-4-N,   N-diäthylcarbamido-       methoxyphenylessigsäure-n-propylester    vom Kp.0.7 210-212¯.



   Beispiel 3
50 g 3-Methoxy-4-N,N-diÏ'thylcarbanudo methoxyphenylessigsäuremlethylester werden in 300 ml Allylalkohol gelöst und nach Zugabe von 0, 1 g Natrium am   Intensivkühler    erhitzt, bis kein   Methano    mehr übergeht. Nachdem der überschüssige Allylalkohol entfernt ist, wird das Produkt unter Vakuum   destilliert,    und man erhält 43 g
3-Methoxy-4-N,   N-diäthylcarbamido-    methoxy-phenylessigsäureallylester vom Kp. o,   8      208-210 .  



  



   Process for the preparation of N-alkyl-substituted 3-methoxy-4-car. alkyl and alkenyl esters of bamidomethoxyphenylacetic acid
It has been found that N-alkylated 3-methoxy4-carbamidomethoxyphenyl acetic acid alkyl and alkenyl esters are surprisingly short-acting narcotics which can be used intravenously and which, compared with the barbituric acid derivatives, which have hitherto been exclusively used for this purpose, differ in animal experiments due to a very rapid decrease in activity and the absence of the so-called Mark ¸overhang¯.



   According to the invention, these compounds are prepared by esterifying corresponding N-alkyl-substituted 3-methoxy-4-carbamidomethoxyphenylacetic acids with saturated or unsaturated aliphatic alcohols or lower N-alkyl-substituted 3-methoxy-4-carbamidomethoxyphenylacetic acid alkyl esters, such as. B. the methyl ester, converted into the corresponding higher esters by transesterification with higher alcohols.



   The 3-methoxy-4-N, N-diethylcarbamidomethoxyphenylacetic acid-n-propyl ester obtainable by the process according to the invention was compared with the known 5-methyl-5-cyclohexenyl-N-methyl-barbituric acid sodium. The following results were obtained in the dog when administered intravenously:
Process comparison product product a) dose 40 mg / kg 40 mg / kg: g b) anesthesia grade 8 VI VI c) total anesthetic time 17 min. 166 min.

      d) anesthetic time from
VI-IV in% of the total anesthetic time * 47% 17%
The results for rabbits are the same
It was accordingly found that with the same dosage, the product obtained by the method according to the invention allows the same depth of anesthesia to be achieved as the comparison product, but with a significantly shorter total anesthetic duration.



  (The total duration of anesthesia is understood to mean the time from the onset of anesthesia to the disappearance of any narcotic symptoms, i.e. up to the point in time at which the animal behaves completely normally again. Transferred to humans, this point in time provides an indication of roadworthiness of the anesthetized individual).



   As a result, the product obtainable according to the invention leads to a considerably faster roadworthiness than the comparative product, an advantage which is of decisive importance especially in minor surgery, where only very short anesthetic times are required. Apart from the comparative product, no such short anesthetic times - when the full tolerance stage has been reached - have become known for the other introduced narcotics to be used intravenously.



   example 1
50 g of 3-methoxy-4-N, N-diethylcarbamidomethoxyphenyl acetic acid methyl ester are dissolved in 300 ml of n-propanol and, after the addition of 0.1 g of sodium n-propoxide, an anesthetic stage VI corresponds to Magnus-Girndt deep anesthesia with complete lack of reflexes; Stage IV anesthesia corresponds to the lateral position with the corneal and pincer intact
Reflex. The time from anesthesia stage VI to IV is roughly a measure of the time available for surgical interventions. seed column heated until no more methanol passes over. After driving off the excess propyl alcohol, the mixture is distilled in vacuo and 46 g of des is obtained
3-Methoxy-4-N, N-diethylcarbamidomethoxyphenylacetic acid n-propyl ester of bp 0.7 210-212¯.



   Example 2
20 g of 3-methoxy-4-N, N-carbamidomethoxyphenylacetic acid (melting point 119-120), which can be obtained from the methyl ester by saponification with alkali, is refluxed with 200 ml of m-propyl alcohol containing 3% hydrogen chloride for 8 hours . After the solvent has been driven off, it is taken up in benzene, washed with sodium carbonate solution and water and dried with sodium sulfate. After driving off the benzene, the residue is distilled in vacuo and 19.8 g are obtained
3-Methoxy-4-N, N-diethylcarbamido methoxyphenyl acetic acid n-propyl ester of boiling point 0.7 210-212¯.



   Example 3
50 g of 3-methoxy-4-N, N-diÏ'thylcarbanudo methoxyphenylessigsäuremlethylester are dissolved in 300 ml of allyl alcohol and, after the addition of 0.1 g of sodium, heated in an intensive cooler until no more methano passes over. After the excess allyl alcohol has been removed, the product is distilled under vacuum and 43 g are obtained
3-Methoxy-4-N, N-diethylcarbamido-methoxy-phenylacetic acid allyl ester of bp. O.8208-210.

 

Claims (1)

PATENTANSPRUCH Verfahren zur Herstellung von N-alkylsubstituierten 3-Methoxy-4-carbamidomethoxyphenylessigsäure- alkyl- und -alkenylestem, dadurch gekennzeichnet, dass man N-alkylsubstituierte 3-Methoxy-4-carbamido- methoxyphenylessigsäuren mit gesättigten oder ungesÏttigten. aliphatischen Alkoholen verestert oder Nalkylsubstituierte 3-Methoxycarbamidomethoxyphe- nylessigsäuremethyl oder-äthylester mit Alikoholen mit mehr als 2 Kohlenstoffatomen umestert. PATENT CLAIM Process for the preparation of N-alkyl-substituted 3-methoxy-4-carbamidomethoxyphenylacetic acid alkyl and alkenyl esters, characterized in that N-alkyl-substituted 3-methoxy-4-carbamido methoxyphenylacetic acids with saturated or unsaturated. aliphatic alcohols esterified or N-alkyl-substituted 3-methoxycarbamidomethoxyphenyl acetic acid methyl or ethyl ester transesterified with alcohols with more than 2 carbon atoms. UNTERANSPRUCH 1. Verfahren nach Patentanspruch, dadurch gekennzeichnet, da¯ der Methylester mit einem ge sättigten oder ungesättigten einwertigen Alkohol um geestert wird. SUBClaim 1. The method according to claim, characterized in that the methyl ester is esterified with a saturated or unsaturated monohydric alcohol.
CH319466A 1960-05-06 1961-04-14 Process for the preparation of N-alkyl-substituted 3-methoxy-4-carbamidomethoxyphenylacetic acid alkyl and alkenyl esters CH415587A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DEF31176A DE1134981B (en) 1960-05-06 1960-05-06 Process for the preparation of N-substituted 3-methoxy-4-carbamidomethoxyphenyl acetic acid alkyl and alkenyl esters

Publications (1)

Publication Number Publication Date
CH415587A true CH415587A (en) 1966-06-30

Family

ID=7094083

Family Applications (2)

Application Number Title Priority Date Filing Date
CH444361A CH425762A (en) 1960-05-06 1961-04-14 Process for the preparation of N-alkyl-substituted 3-methoxy-4-carbamidomethoxyphenylacetic acid alkyl and alkenyl esters
CH319466A CH415587A (en) 1960-05-06 1961-04-14 Process for the preparation of N-alkyl-substituted 3-methoxy-4-carbamidomethoxyphenylacetic acid alkyl and alkenyl esters

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CH444361A CH425762A (en) 1960-05-06 1961-04-14 Process for the preparation of N-alkyl-substituted 3-methoxy-4-carbamidomethoxyphenylacetic acid alkyl and alkenyl esters

Country Status (5)

Country Link
BE (1) BE603477A (en)
CH (2) CH425762A (en)
DE (1) DE1134981B (en)
DK (1) DK104841C (en)
GB (1) GB906250A (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1300545B (en) * 1965-02-24 1969-08-07 Bayer Ag Process for the preparation of 2- (N, N-dialkyl- or N-alkyl-N-alkoxy-carbamoyl-methoxy) -benzoic acid esters substituted in the 5-position
IT1204778B (en) 1986-02-04 1989-03-10 Mazzarella Basilio INJECTABLE PHARMACEUTICAL FORMULATIONS OF ACTIVE INGREDIENTS FOR GENERAL ANESTHETIC ACTIVITIES
PL207038B1 (en) 2002-01-25 2010-10-29 Theravance Short-acting sedative hypnotic agents for anesthesia and sedation
JP4153949B2 (en) * 2002-05-09 2008-09-24 セラヴァンス, インコーポレーテッド Short-acting sedative hypnotics for anesthesia and sedation
DK1648413T3 (en) 2003-07-23 2010-01-11 Theravance Inc Pharmaceutical preparations of short-acting sedative sleep-spraying agent

Also Published As

Publication number Publication date
DK104841C (en) 1966-07-11
CH425762A (en) 1966-12-15
GB906250A (en) 1962-09-19
DE1134981B (en) 1962-08-23
BE603477A (en) 1961-11-06

Similar Documents

Publication Publication Date Title
DE2635853A1 (en) PYRROLIDINE-2-ON DERIVATIVES, THE PROCESS FOR THEIR MANUFACTURING AND THE MEDICINAL PRODUCT CONTAINING THEY
DE2036421C (en)
CH415587A (en) Process for the preparation of N-alkyl-substituted 3-methoxy-4-carbamidomethoxyphenylacetic acid alkyl and alkenyl esters
EP0133935B1 (en) P-oxybenzoic acid derivatives, methods for preparing them, and their use for the preparation of medicaments with hypolipemic activity
CH638510A5 (en) PROSTACYCLINANALOGA.
DE2350148A1 (en) THIOPHENE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS
CH628632A5 (en) METHOD FOR THE PRODUCTION OF FIELD ACID ESTERS OF PHENOTHIAZINE DERIVATIVES.
DE2817494A1 (en) AMINO ALCOHOL DERIVATIVE
CH621786A5 (en) Process for the preparation of a novel behenic acid ester
DE2503135C3 (en) Terpene compounds, processes for their preparation and pharmaceuticals containing these products
DE3013502C2 (en) [2 "- (Trifluoromethyl) -phenthiazin-10" -yl- (n-prop-3 "" ylpiperazin-4 "" - yleth-2 "" "- yl)] ester, method for the production of the same and medicinal products containing them
EP0019069A2 (en) 6-Keto PGE1 compounds, their preparation and therapeutic application, PGI1 compounds
DE2438884A1 (en) NEW DERIVATIVES OF 5-HYDROXYMETHYLTHIAZOLE, THE PROCESS FOR THEIR MANUFACTURING AND PHARMACEUTICAL COMPOSITIONS
DE2211214A1 (en) Thiophendenvates and processes for their preparation
CH441272A (en) Process for the preparation of substituted 3,4-dihydroxybenzoic acid esters
AT224631B (en) Process for the preparation of new N-alkyl-substituted 3-methoxy-4-carbamidomethoxyphenylacetic acid alkyl and alkenyl esters
DE1018070B (en) Process for the preparation of anesthetically active N-alkylaminocarboxylic acid anilides
DE2141357C3 (en) Bis (4-chlorophenoxy) acetic acid esters, process for their preparation, medicaments containing these compounds
DE2616657A1 (en) OXADIAZOLE DERIVATIVES AND THEIR SALTS, PROCESS FOR THEIR MANUFACTURING AND PHARMACEUTICAL COMPOSITIONS
DE603088C (en) Process for the preparation of a physiologically highly effective conversion product from vitamin D irradiated with ultraviolet rays
AT160397B (en) Process for the preparation of l-ascorbic acid.
DE2404924A1 (en) ERGOLINE DERIVATIVES
DE1097986B (en) Process for the production of 6ª ‡ -Methyl-17ª ‡ -oxyprogesterone and its esters
DE1543842C3 (en) 3-Oxo-2-oxa-4,9, l 1-gonatriene, process for their preparation and pharmaceuticals containing them
CH205522A (en) Process for the preparation of a 20-ketone of the cyclopentanopolyhydrophenanthrene series.